Co-Diagnostics PE Ratio 2017-2024 | CODX
Current and historical p/e ratio for Co-Diagnostics (CODX) from 2017 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Co-Diagnostics PE ratio as of January 29, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Co-Diagnostics PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-01-30 | 0.79 | 0.00 | |
| 2024-09-30 | 1.25 | $-1.38 | 0.00 |
| 2024-06-30 | 1.25 | $-1.26 | 0.00 |
| 2024-03-31 | 1.12 | $-1.32 | 0.00 |
| 2023-12-31 | 1.33 | $-1.21 | 0.00 |
| 2023-09-30 | 1.06 | $-1.39 | 0.00 |
| 2023-06-30 | 1.11 | $-1.23 | 0.00 |
| 2023-03-31 | 1.48 | $-1.00 | 0.00 |
| 2022-12-31 | 2.52 | $-0.46 | 0.00 |
| 2022-09-30 | 3.21 | $0.47 | 6.83 |
| 2022-06-30 | 5.61 | $0.89 | 6.30 |
| 2022-03-31 | 6.18 | $1.30 | 4.75 |
| 2021-12-31 | 8.93 | $1.22 | 7.32 |
| 2021-09-30 | 9.73 | $1.40 | 6.95 |
| 2021-06-30 | 8.25 | $1.55 | 5.32 |
| 2021-03-31 | 9.54 | $1.65 | 5.78 |
| 2020-12-31 | 9.30 | $1.34 | 6.94 |
| 2020-09-30 | 13.59 | $0.81 | 16.78 |
| 2020-06-30 | 19.35 | $0.18 | 107.50 |
| 2020-03-31 | 7.62 | $-0.33 | 0.00 |
| 2019-12-31 | 0.90 | $-0.37 | 0.00 |
| 2019-09-30 | 1.03 | $-0.27 | 0.00 |
| 2019-06-30 | 0.80 | $-0.17 | 0.00 |
| 2019-03-31 | 1.06 | $-0.09 | 0.00 |
| 2018-12-31 | 1.49 | 0 | 0.00 |
| 2018-09-30 | 2.63 | 0 | 0.00 |
| 2018-06-30 | 3.88 | 0 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.025B | $0.007B |
| Co-Diagnostics Inc. is a molecular diagnostics company. It develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company's technology is utilized for tests which are designed using the detection and/or analysis of nucleic acid molecules. It also uses proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers. Co-Diagnostics Inc. is based in UT, United States. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $92.839B | 12.14 |
| Cencora (COR) | United States | $49.468B | 18.60 |
| DiDi Global (DIDIY) | China | $22.650B | 0.00 |
| Natera (NTRA) | United States | $22.209B | 0.00 |
| ICON (ICLR) | Ireland | $16.344B | 14.56 |
| Revvity (RVTY) | United States | $15.033B | 26.11 |
| Avantor (AVTR) | United States | $14.626B | 21.93 |
| BioMerieux (BMXMF) | France | $14.203B | 0.00 |
| Viatris (VTRS) | United States | $13.523B | 4.17 |
| CochLear (CHEOY) | Australia | $12.916B | 0.00 |
| Solventum (SOLV) | United States | $12.870B | 0.00 |
| Doximity (DOCS) | United States | $10.767B | 63.37 |
| Medpace Holdings (MEDP) | United States | $10.662B | 30.04 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $10.135B | 0.00 |
| HealthEquity (HQY) | United States | $9.429B | 47.30 |
| Sonic Healthcare (SKHHY) | Australia | $8.657B | 0.00 |
| Charles River Laboratories (CRL) | United States | $8.266B | 15.97 |
| Bausch + Lomb (BLCO) | Canada | $6.301B | 29.31 |
| Amplifon S.p.A (AMFPF) | Italy | $6.136B | 31.28 |
| BrightSpring Health Services (BTSG) | United States | $4.136B | 87.96 |
| Organon (OGN) | United States | $4.079B | 4.11 |
| Sotera Health (SHC) | United States | $3.875B | 20.73 |
| Surgery Partners (SGRY) | United States | $3.273B | 37.32 |
| Concentras Parent (CON) | United States | $2.998B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $2.937B | 0.00 |
| Premier (PINC) | United States | $2.191B | 11.40 |
| Ardent Health Partners (ARDT) | United States | $2.098B | 0.00 |
| PACS (PACS) | United States | $2.080B | 0.00 |
| GeneDx Holdings (WGS) | United States | $2.079B | 0.00 |
| Progyny (PGNY) | United States | $1.980B | 40.09 |
| GoodRx Holdings (GDRX) | United States | $1.845B | 48.40 |
| Teladoc Health (TDOC) | United States | $1.782B | 0.00 |
| Agilon Health (AGL) | United States | $1.413B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.409B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.219B | 11.92 |
| CareDx (CDNA) | United States | $1.210B | 0.00 |
| Embecta (EMBC) | United States | $1.070B | 7.48 |
| AMN Healthcare Services Inc (AMN) | United States | $1.036B | 7.02 |
| Establishment Labs Holdings (ESTA) | $0.947B | 0.00 | |
| Auna S.A (AUNA) | Luxembourg | $0.637B | 0.00 |
| SBC Medicals (SBC) | United States | $0.518B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.505B | 0.00 |
| DocGo (DCGO) | United States | $0.490B | 18.46 |
| QDM (QDMI) | Hong Kong, SAR China | $0.480B | 12.56 |
| Sonida Senior Living (SNDA) | United States | $0.451B | 0.00 |
| Enhabit (EHAB) | United States | $0.422B | 36.52 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.280B | 0.00 |
| MultiPlan (MPLN) | United States | $0.267B | 0.00 |
| LifeMD (LFMD) | United States | $0.248B | 0.00 |
| Nutex Health (NUTX) | United States | $0.243B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.212B | 0.00 |
| Beauty Health (SKIN) | United States | $0.205B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.184B | 0.00 |
| Biodesix (BDSX) | United States | $0.151B | 0.00 |
| So-Young (SY) | China | $0.105B | 17.83 |
| Ascend Wellness Holdings (AAWH) | United States | $0.079B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.068B | 0.00 |
| ModivCare (MODV) | United States | $0.066B | 3.57 |
| Oncology Institute (TOI) | United States | $0.063B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 1.61 |
| Singular Genomics Systems (OMIC) | United States | $0.050B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.038B | 0.00 |
| OncoCyte (OCX) | United States | $0.034B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.024B | 0.00 |
| KindlyMD (KDLY) | United States | $0.008B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.008B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.007B | 0.00 | |
| XWELL (XWEL) | United States | $0.007B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| Aclarion (ACON) | United States | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |